• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一个经受过刺激的树突状细胞可以成为CD4 +辅助性T细胞和杀伤性T细胞之间的临时桥梁。

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.

作者信息

Ridge J P, Di Rosa F, Matzinger P

机构信息

Ghost lab, Section on T cell Tolerance and Memory, Laboratory of Cellular and Molecular Immunology, NIAID/NIH, Bethesda, Maryland 20892, USA.

出版信息

Nature. 1998 Jun 4;393(6684):474-8. doi: 10.1038/30989.

DOI:10.1038/30989
PMID:9624003
Abstract

To generate an immune response, antigen-specific T-helper and T-killer cells must find each other and, because they cannot detect each other's presence, they are brought together by an antigen-loaded dendritic cell that displays antigens to both. This three-cell interaction, however, seems nearly impossible because all three cell types are rare and migratory. Here we provide a potential solution to this conundrum. We found that the three cells need not meet simultaneously but that the helper cell can first engage and 'condition' the dendritic cell, which then becomes empowered to stimulate a killer cell. The first step (help) can be bypassed by modulation of the surface molecule CD40, or by viral infection of dendritic cells. These results may explain the long-standing paradoxical observation that responses to some viruses are helper-independent, and they evoke the possibility that dendritic cells may take on different functions in response to different conditioning signals.

摘要

为了产生免疫反应,抗原特异性辅助性T细胞和杀伤性T细胞必须相互找到对方,然而由于它们无法检测到彼此的存在,因此由负载抗原的树突状细胞将它们聚集在一起,该树突状细胞会向两者展示抗原。然而,这种三细胞相互作用似乎几乎是不可能的,因为这三种细胞类型都很罕见且具有迁移性。在这里,我们提供了一个解决这一难题的潜在方案。我们发现这三种细胞不必同时相遇,辅助性T细胞可以首先与树突状细胞结合并使其“预处理”,然后树突状细胞就有能力刺激杀伤性T细胞。第一步(辅助作用)可以通过调节表面分子CD40或通过树突状细胞的病毒感染来绕过。这些结果可能解释了长期存在的矛盾观察结果,即对某些病毒的反应是不依赖辅助性T细胞的,并且它们引发了一种可能性,即树突状细胞可能会根据不同的预处理信号发挥不同的功能。

相似文献

1
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.一个经受过刺激的树突状细胞可以成为CD4 +辅助性T细胞和杀伤性T细胞之间的临时桥梁。
Nature. 1998 Jun 4;393(6684):474-8. doi: 10.1038/30989.
2
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.细胞毒性T淋巴细胞的T细胞辅助作用由CD40-CD40L相互作用介导。
Nature. 1998 Jun 4;393(6684):480-3. doi: 10.1038/31002.
3
Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells.通过CD40或Toll样受体(TLR)刺激在树突状细胞上诱导CD70有助于在缺乏CD4 + T细胞的情况下CD8 + T细胞反应的发展。
J Immunol. 2005 Jan 15;174(2):710-7. doi: 10.4049/jimmunol.174.2.710.
4
Engaging the CD40-CD40L pathway augments T-helper cell responses and improves control of Mycobacterium tuberculosis infection.激活CD40-CD40L通路可增强辅助性T细胞反应并改善对结核分枝杆菌感染的控制。
PLoS Pathog. 2017 Aug 2;13(8):e1006530. doi: 10.1371/journal.ppat.1006530. eCollection 2017 Aug.
5
Stimulation with dendritic cells decreases or obviates the CD4+ helper cell requirement in cytotoxic T lymphocyte responses.用树突状细胞刺激可降低或消除细胞毒性T淋巴细胞反应中对CD4+辅助性T细胞的需求。
Eur J Immunol. 1988 Feb;18(2):219-23. doi: 10.1002/eji.1830180206.
6
The roles of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA.MHC II类分子、CD40和B7共刺激分子在质粒DNA诱导细胞毒性T淋巴细胞中的作用。
J Immunol. 2001 Mar 1;166(5):3061-6. doi: 10.4049/jimmunol.166.5.3061.
7
TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation.TRANCE,一种对不依赖CD40配体的T辅助细胞激活至关重要的肿瘤坏死因子家族成员。
J Exp Med. 1999 Apr 5;189(7):1025-31. doi: 10.1084/jem.189.7.1025.
8
Dendritic cells need T cell help to prime cytotoxic T cell responses to strong antigens.树突状细胞需要T细胞的辅助来启动针对强抗原的细胞毒性T细胞反应。
Eur J Immunol. 1999 Sep;29(9):2826-34. doi: 10.1002/(SICI)1521-4141(199909)29:09<2826::AID-IMMU2826>3.0.CO;2-M.
9
Help for cytotoxic-T-cell responses is mediated by CD40 signalling.细胞毒性T细胞反应的辅助作用由CD40信号传导介导。
Nature. 1998 Jun 4;393(6684):478-80. doi: 10.1038/30996.
10
Lipopolysaccharide modulation of dendritic cells is insufficient to mature dendritic cells to generate CTLs from naive polyclonal CD8+ T cells in vitro, whereas CD40 ligation is essential.脂多糖对树突状细胞的调节不足以使树突状细胞在体外从初始多克隆CD8⁺T细胞生成细胞毒性T淋巴细胞(CTL),而CD40连接是必不可少的。
J Immunol. 2001 Dec 1;167(11):6247-55. doi: 10.4049/jimmunol.167.11.6247.

引用本文的文献

1
Therapeutic Efficacy of CD34-Derived Allogeneic Dendritic Cells Engineered to Express CD93, CD40L, and CXCL13 in Humanized Mouse Models of Pancreatic Cancer.在胰腺癌人源化小鼠模型中,经工程改造表达CD93、CD40L和CXCL13的CD34来源的同种异体树突状细胞的治疗效果。
Vaccines (Basel). 2025 Jul 12;13(7):749. doi: 10.3390/vaccines13070749.
2
CD4 T cells license Kupffer cells to reverse CD8 T cell dysfunction induced by hepatocellular priming.CD4 T细胞使库普弗细胞具备逆转由肝细胞致敏诱导的CD8 T细胞功能障碍的能力。
Nat Immunol. 2025 Jun 30. doi: 10.1038/s41590-025-02199-3.
3
CD154:CD11b blockade enhances CD8+ T cell differentiation during infection but not transplantation.
CD154:CD11b阻断在感染期间而非移植过程中增强CD8 + T细胞分化。
JCI Insight. 2025 Jun 9;10(11). doi: 10.1172/jci.insight.184843.
4
Efficacy of Using Dendritic Cells in the Treatment of Prostate Cancer: A Systematic Review.使用树突状细胞治疗前列腺癌的疗效:一项系统评价
Int J Mol Sci. 2025 May 21;26(10):4939. doi: 10.3390/ijms26104939.
5
CD8 T cell-derived CD40L mediates noncanonical cytotoxicity in CD40-expressing cancer cells.CD8 T细胞衍生的CD40L介导表达CD40的癌细胞中的非经典细胞毒性。
Sci Adv. 2025 May 23;11(21):eadr9331. doi: 10.1126/sciadv.adr9331. Epub 2025 May 21.
6
A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma.一种RAS(激活态)多选择性抑制剂联合疗法通过胰腺导管腺癌中衰老相关的肿瘤-免疫平衡触发长期肿瘤控制。
Cancer Discov. 2025 Aug 4;15(8):1717-1739. doi: 10.1158/2159-8290.CD-24-1425.
7
Bidirectional Communication Between the Innate and Adaptive Immune Systems.先天性免疫系统与适应性免疫系统之间的双向通讯
Annu Rev Immunol. 2025 Apr;43(1):489-514. doi: 10.1146/annurev-immunol-083122-040624.
8
Facts and Hopes of CD40 Agonists in Cancer Immunotherapy.CD40 激动剂在癌症免疫治疗中的事实与希望
Clin Cancer Res. 2025 Jun 3;31(11):2079-2087. doi: 10.1158/1078-0432.CCR-24-1660.
9
Cross-priming in cancer immunology and immunotherapy.癌症免疫学与免疫治疗中的交叉呈递
Nat Rev Cancer. 2025 Apr;25(4):249-273. doi: 10.1038/s41568-024-00785-5. Epub 2025 Jan 29.
10
Sex-Related Differences in the Immune System Drive Differential Responses to Anti-PD-1 Immunotherapy.免疫系统中的性别差异导致对抗PD-1免疫疗法的不同反应。
Biomolecules. 2024 Nov 27;14(12):1513. doi: 10.3390/biom14121513.